The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose ...
A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors. This is an ASCO Meeting Abstract from ...
Swedish firm Alligator Bioscience and Seattle-based Aptevo Therapeutics have agreed to co-develop ALG.APV-527, a bispecific antibody for tumor-directed immunotherapy, which is based on Alligator’s ...
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of ...
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody ...
Conventionally, the first and second stimulation signals in vitro, simulating the process in vivo, are achieved using anti-CD3 antibody, anti-CD28 antibody, or CD3/CD28 magnetic beads, along with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results